Introduction: Belimumab (BEL) is a monoclonal antibody which inhibits binding of B-cell-activating factor (BAFF) to its receptors on B cells, thus inhibiting the survival of alloreactive B cells. Given the role of B cells and BAFF in chronic Graft-versus-Host Disease (cGvHD) pathophysiology, BEL might have a role in prevention of cGvHD. We hypothesized that targeting […]
30. Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease
